Navigation Links
3-Drug Combo Reduces Nausea After Chemo
Date:5/11/2009

Study finds adding casopitant mesylate to regimen cuts side effects

MONDAY, May 11 (HealthDay News) -- The addition of the drug casopitant mesylate (CM) to the conventional two-drug regimen of dexamethasone and ondansetron greatly reduces chemotherapy-induced nausea and vomiting (CINV) in patients undergoing highly emetogenic chemotherapy (HEC), a new study concludes.

HEC is used to treat many types of solid tumor cancers, including colorectal and pancreatic cancer. Drugs such as dexamethasone and ondansetron are effective in reducing CINV in the first 24 hours after chemotherapy but only provide moderate relief during the delayed phase (24 to 120 hours after chemotherapy).

The phase 3 study included 810 patients who were receiving dexamethasone and ondansetron after undergoing HEC. They were randomly selected to also receive either a placebo (269 patients), a single 150-milligram oral dose of CM (271), or three-day intravenous plus oral CM (90-mg intravenous on the first day plus 50-mg oral on the second and third days).

The study found that 86 percent of patients in the single oral CM group and 80 percent of those in the intravenous plus oral CM group achieved a complete response (no vomiting, retching or use of rescue medications) for the first 120 hours after their first cycle of HEC treatment, compared with 66 percent of patients in the placebo group.

"A three-drug regimen including a single oral dose or three-day intravenous plus oral regimen of casopitant mesylate plus dexamethasone and ondansetron significantly reduced CINV events in patients receiving HEC compared with a two-drug regimen of dexamethasone and ondansetron," wrote Steven Grunberg, a professor at the University of Vermont, Burlington, and colleagues.

The study appears online and in the June print edition of The Lancet Oncology.

More information

The U.S. National Cancer Institute has more about managing chemotherapy-related nausea and vomiting.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, May 10, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. 3-drug combination extremely promising as first-line therapy for multiple myeloma
2. 3-Drug Combo Improves Advanced Pancreatic Cancer Outcomes
3. 3-drug chemotherapy combination increases organ preservation in patients with larynx cancer
4. Radiation and drug combo helps boost efficacy of lung cancer treatment
5. Aerobic, Weight Training Combo Best Against Diabetes
6. New antibiotic drug combo to speed up treatment of tuberculosis
7. Drug Combo Helps Fight Marfan Syndrome
8. Drug Combo Blocks Pain Without Impairing Movement
9. Two-Drug Combo Fights Brain Tumors
10. CPR, Defibrillator Combo Boosts Cardiac Incident Survival
11. Drug Combo Boosts Multiple Myeloma Survival
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
3-Drug Combo Reduces Nausea After Chemo
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
Breaking Medicine Technology: